A5028285577- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Pregnancy and Medication Impact
- Celiac Disease Research and Management
- Systemic Lupus Erythematosus Research
- SARS-CoV-2 and COVID-19 Research
- Mycobacterium research and diagnosis
- Gastrointestinal disorders and treatments
- Gastrointestinal Bleeding Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Diagnosis and treatment of tuberculosis
- Diverticular Disease and Complications
- COVID-19 and healthcare impacts
- Galectins and Cancer Biology
- Gastrointestinal motility and disorders
- Liver Diseases and Immunity
- Biosimilars and Bioanalytical Methods
- Tuberculosis Research and Epidemiology
- Gastric Cancer Management and Outcomes
- Reproductive System and Pregnancy
Evangelismos Hospital
2015-2024
Ospedale San Filippo Neri
2024
Hygeia Hospital
2023-2024
Polyclinic General Hospital
2015-2022
GTx (United States)
2004-2021
Polyclinic Medical Center
2020
Athens Medical Center
2010-2019
NIMTS Hospital
2006-2017
Ibero American University
2016
National and Kapodistrian University of Athens
1995-2016
The comparative efficacy and safety of infliximab azathioprine therapy alone or in combination for Crohn's disease are unknown.
This paper is the first in a series of two publications relating to European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on diagnosis management disease concerns methodology process, classification, medical active quiescent disease. Surgical as well special situations including perianal this ECCO Consensus are covered subsequent second [Gionchetti et al JCC 2016].
### 5.1 General When deciding the appropriate treatment strategy for active ulcerative colitis one should consider activity, distribution (proctitis, left-sided, extensive1), and pattern of disease. The disease includes relapse frequency, course disease, response to previous medications, side-effect profile medication extra-intestinal manifestations. age at onset duration may also be important factors. #### 5.1.1 Disease activity The principal activity scoring systems used in clinical...
The strategy to reach the Consensus on guideline revisions involved six steps:1. Guideline statements of 2004 were analysed systematically by chairs working parties.Guideline selected for change and questions unresolved ECCO guidelines distributed party members.Participants asked answer based their experience as well evidence from literature (Delphi procedure). 62. In parallel, parties performed a systematic search topic with appropriate key words using Medline/Pubmed Cochrane database, own...
### 1.1 Introduction Ulcerative colitis is a lifelong disease arising from an interaction between genetic and environmental factors, observed predominantly in the developed countries of world. The precise aetiology unknown therefore medical therapy to cure not yet available. Within Europe there North–South gradient, but incidence appears have increased Southern Eastern recent years.1,2 Patients may live with considerable symptom burden despite treatment (66% describe interference work 73%...
The histologic examination of endoscopic biopsies or resection specimens remains a key step in the work-up affected inflammatory bowel disease (IBD) patients and can be used for diagnosis differential diagnosis, particularly differentiation UC from CD other non-IBD related colitides. introduction new treatment strategies interfering with patients' immune system may result mucosal healing, making pathologists aware impact upon diagnostic features. European Crohn's Colitis Organisation (ECCO)...
### 1.1 Introduction Ulcerative colitis is a life long disease arising from an interaction between genetic and environmental factors, but observed predominantly in the developed countries of world. The precise aetiology unknown therefore medical therapy to cure not yet available. Within Europe there North–South gradient, incidence appears have increased Southern developing recent years.1,2 Patients may live with considerable symptom burden despite treatment (66% describe interference work...
<h3>Background and aims</h3> The Crohn9s Disease Activity Index (CDAI) has been criticised due to heavy weighting on subjective clinical symptoms. C-reactive protein (CRP) endoscopic lesions are objective measures of inflammation. We investigated the relationships between disease activity, CRP normalisation mucosal healing in (CD). <h3>Methods</h3> Study Biologic Immunomodulator Naive Patients CD trial compared infliximab azathioprine plus 508 patients. Mucosal was defined as absence...
MicroRNAs (miRNAs) consist of a group small noncoding RNAs that partially regulate gene expression. We investigated the expression patterns commonly deregulated miRNAs in Crohn's disease (CD) and ulcerative colitis (UC) peripheral blood samples inflammatory bowel patients.This study consisted 128 CD 88 UC patients, as well 162 healthy controls. The miRNA species were quantitatively assayed using reverse transcription real-time RT-PCR. Stem-loop complementary DNAs (cDNAs) synthesized looped...
Biosimilars of infliximab were first approved by the European Medicine Agency in 2013,1 , 2 based on pre-clinical studies biosimilarity and clinical data coming from two randomised controlled trials conducted rheumatoid arthritis [RA] ankylosing spondylitis [AS].3 4 Initially Crohn’s Colitis Organisation [ECCO] raised some caution use biosimilars.5 This cautious approach was also supported several national inflammatory bowel disease [IBD] societies5–12 [Table 1]. An insufficient...
Abstract Background and Aims This study aimed to compare real-world clinical effectiveness safety of vedolizumab, an α4β7-integrin inhibitor, anti-tumour necrosis factor-α [anti-TNFα] agents in biologic-naïve ulcerative colitis [UC] Crohn’s disease [CD] patients. Methods was a 24-month retrospective medical chart adult UC CD patients treated with vedolizumab or anti-TNFα Canada, Greece the USA. Inverse probability weighting used account for differences between groups. Primary outcomes were...
Summary Background As treatment goals in Crohn's disease ( CD ) evolve, targets now include clinical remission CR ), mucosal healing MH and biological [C‐reactive protein normalisation CRP norm )]. Aims To evaluate the association of baseline factors with achievement different composite parameters at week 26. Methods This post hoc analysis SONIC trial evaluated measures 26 a subgroup patients activity index CDAI scores, , endoscopic data available N = 188). Assessed were: < 150) (absence...
The effects of azathioprine (AZA) and budesonide (BUD) on mucosal healing histologic remission Crohn's disease (CD) are insufficiently studied. In this prospective study we evaluated the comparative AZA BUD endoscopic activity in patients with steroid-dependent ileocolitis or proximal colitis who had achieved clinical conventional steroids.Patients were randomized to (2.0-2.5 mg/kg a day) (6-9 mg for 1 year. protocol included examination, laboratory tests, calculation Disease Activity Index...
Extraintestinal manifestations [EIMs] are common in inflammatory bowel disease [IBD]. Data on epidemiology and risk factors of EIMs IBD patients limited. The aim this study was to investigate the prevalence a large cohort Greek identify for their development.The population consisted patients, who were followed eight tertiary hospitals. Demographic clinical characteristics analysed. diagnosis based standard criteria specialist consultation.In total, 1860 (1001 with Crohn's [CD], 859...
Background and aim Disease activity for Crohn's disease (CD) UC is typically defined based on symptoms at a moment in time, ignores the long-term burden of disease. The aims this study were to select attributes determining overall severity, rank importance score these individual both CD UC. Methods Using modified Delphi panel, 14 members International Organization Study Inflammatory Bowel Diseases (IOIBD) selected most important related IBD. Eighteen IOIBD then completed statistical exercise...
Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving interval superior doubling dose. We aimed assess efficacy of dose intensification by interval-halving compared with dose-doubling. A multicenter retrospective study CD was undertaken. The clinical outcome whose infusion intervals were halved (5 mg/kg/4 weeks) treated dose-doubling (10 mg/kg/8 weeks). In all, 168 included from 18 centers Europe, USA,...
Aim: To establish whether the addition of probiotics to a globally accepted Helicobacter pylori (H. pylori)-eradication scheme may reduce rates side effects and increase eradication rates. Methods. Prospective, randomized, placebo-controlled trial patients receiving therapy for H. in eight participating centers. All received 10-day proton pump inhibitor containing non-bismuth quadruple therapeutic regimen (omeprazole 20 mg, amoxycillin 1 g, clarithromycin 500 metronidazole mg all twice daily...
Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and compare anti-tumour necrosis factor [anti-TNF] therapy vedolizumab [VDZ] ustekinumab [UST] real-world setting. A retrospective multicentre study CD-adults curative ICR on was undertaken. ePOR defined as Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD 6. Multivariable logistic regression...